MX2023001385A - Metodos de tratamiento usando furosemida. - Google Patents

Metodos de tratamiento usando furosemida.

Info

Publication number
MX2023001385A
MX2023001385A MX2023001385A MX2023001385A MX2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A MX 2023001385 A MX2023001385 A MX 2023001385A
Authority
MX
Mexico
Prior art keywords
methods
furosemide
treatment
patient
edema
Prior art date
Application number
MX2023001385A
Other languages
English (en)
Inventor
John F Mohr
John Tucker
Michael Hassman
Erik Mark Pecorelli
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of MX2023001385A publication Critical patent/MX2023001385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Se describe en la presente, los métodos para administrar subcutáneamente formulaciones farmacéuticas líquidas de furosemida a un paciente adulto a partir de un cartucho prellenado usando un perfil de suministro bifásico de cinco horas. Se proporcionan también los métodos de tratamiento de la congestión, edema, sobrecarga de fluidos, o hipertensión en un paciente en necesidad de estos.
MX2023001385A 2020-08-05 2021-08-05 Metodos de tratamiento usando furosemida. MX2023001385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061518P 2020-08-05 2020-08-05
PCT/US2021/044723 WO2022031959A1 (en) 2020-08-05 2021-08-05 Methods of treatment using furosemide

Publications (1)

Publication Number Publication Date
MX2023001385A true MX2023001385A (es) 2023-03-03

Family

ID=77774970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001385A MX2023001385A (es) 2020-08-05 2021-08-05 Metodos de tratamiento usando furosemida.

Country Status (9)

Country Link
US (1) US20230270759A1 (es)
EP (1) EP4192473A1 (es)
JP (1) JP2023536730A (es)
CN (1) CN116322704A (es)
AU (1) AU2021320308A1 (es)
CA (1) CA3190585A1 (es)
IL (1) IL300152A (es)
MX (1) MX2023001385A (es)
WO (1) WO2022031959A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512650A (ja) * 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6595961B2 (en) * 2001-04-16 2003-07-22 Becton, Dickinson And Company Sterilizable transfer or storage device for medicaments, drugs and vaccines
JP6415535B2 (ja) * 2013-04-05 2018-10-31 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下投与用の医薬製剤
EP3893843A1 (en) * 2018-12-10 2021-10-20 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof

Also Published As

Publication number Publication date
CA3190585A1 (en) 2022-02-10
WO2022031959A1 (en) 2022-02-10
EP4192473A1 (en) 2023-06-14
US20230270759A1 (en) 2023-08-31
CN116322704A (zh) 2023-06-23
IL300152A (en) 2023-03-01
AU2021320308A1 (en) 2023-03-02
JP2023536730A (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
NZ601704A (en) Drug delivery system for dosage control having a pump and a controller
KR101900520B1 (ko) 복합 조성물
JP2015187125A5 (es)
MX2023001385A (es) Metodos de tratamiento usando furosemida.
RU2012110324A (ru) Способы лечения хронического нейрогенного воспаления с помощью модифицированного клостридиального токсина
Fu et al. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis
HRP20110914T1 (hr) Kombinacija flupirtina i tramadola
Mameli et al. Bromelain: an overview of applications in medicine and dentistry
CA2411814A1 (fr) Seringue sans aiguille munie d'un reservoir modulable
JP2013040195A5 (es)
MX2021010356A (es) SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
AR025343A1 (es) Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante
MX2021009084A (es) Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
MX2022003051A (es) Formulaciones para la administracion de farmacos.
Duarte et al. Iloprost infusion through elastomeric pump for the out patient treatment of severe Raynaud’s phenomenon and digital ulcers–a single centre experience
RU2758124C1 (ru) Устройство для внутривенных инфузий при озонотерапии
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
Shields et al. AU-011, a targeted therapy for primary treatment of choroidal melanoma (CM) via intravitreal (IVT) or surachoroidal (SC) administration
WO2018136647A3 (en) Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
Arcinue et al. Corticosteroids in uveitis
RU2345760C1 (ru) Способ лечения расстройства полового влечения (либидо) у мужчин
RU2233657C2 (ru) Способ лечения красного плоского лишая
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
Lin et al. Therapeutic Effects of Intra-articular Botulinum Toxin Type A in Knee Osteoarthritis